Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Pediatric designation is rare , especially for rare diseases
Of the 402 orphan indications, 136 (33.8%) were pediatric. These 136 indications targeted 87 unique diseases; 21 diseases were targeted by ≥1 indication. Of the 136 pediatric orphan indications, 60 (44.1%) were for novel drugs, 45 (33.1%) were for non-novel drugs approved to treat ≥1 common disease, and 31 (22.8%) were for non-novel drugs approved only to treat rare diseases. Among 97 indications eligible for breakthrough designation, 20 (20.6%) received this designation.
Actually Mr Jinx originally I merely pointed out that my experience with micky was that he was a trader and talked his own book which was his choice This led to being called a knbhd.
On reflection trying to scare investors into selling is akin to ripping off old ladies, so if you are OK with it (not that I care) I stand by my earlier statement.
Oi Micky, you predict what suits your book, plucking figures from thin air does not make you a guru.
You are no different to someone who charges an old lady 2 grand to replace a roof tile, your just a low level tea leaf.
With most placings the majority of the shares are pre-sold, in this case probably above 3p.
The market makers will run a negative posistion as they know the stock will quickly be replaced to balance the books.
once announced the placees are happy to dump the remainder at cost or even below and move on to the next mark as their business is placings not investment.
Add in scared PI's and you need a good volume to finally clear the last few. Today is low volume so without news you may have to endure this all week.
look back at mickys posts for the last couple of years, he is a trader which is fine but he just posts to suit his position.
Would be nice if people were a bit more genuine but thats the world we live in.
Cheers Guys
It clearly states anything over 2 million dollars has to be matched. This would mean that HEMO would need to have 4m ringfenced for CBR to qualify for the full amount which without the raise would have left little to advance other projects.
You cannot negotiate with big pharma from a position of weakness, money needed to be raised and to equate the issue price with the 4p herd madness level that we reached last week is stupid.
If we had gone from 1.2p to 3p over that period and then done a raise of 4m at 2.5p most would have seen it as a sensible business decision.
there will be more fundraising but now should be at lower volume and higher strike price.
It was this statement from the September letter that interested me.
"Revenue from annual subscription renewals from our existing clients continue to fuel our business as well as our financial sponsorship of the Phase I clinical trial"
It is sustaining both the business and the trial according to the letter.
I am just not sure we are waiting for CLN's or a placing as cash may not be required.
Options would be the best way for the directors to profit and looking back none have been issued for a very long time.